Marc Stapley

Marc Stapley (chief executive) discloses dealings in 3 companies, chiefly Veracyte, Inc., GLAUKOS Corp and Illumina, Inc. In total, 48 filings cover trades dated from 20 January 2016 to 2 September 2026.

Market trades split into 1 purchase (€923k) and 4 sales (€1.9M). Taken together, the sales exceed the purchases by €964k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 38 share grants and 5 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

The latest filing, published on 4 September 2026, reports a share grant of €340k in Veracyte, Inc. The clock since the last published purchase (13 June 2022) now reads 1,588 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.